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qPCRAbstract There is a lack of consensus on whether the role of folate in cancer cells is protective or
harmful. The use of folates in combination with cancer-targeting therapeutic regimens requires
detailed information to ensure their safe and proper use. Therefore, we evaluated the effects of folic
acid (FA) in combination with the chemotherapeutic compounds doxorubicin (DXR), camp-
tothecin (CPT) and methyl methanesulfonate (MMS) on the growth of MCF-7 cells. The data gen-
erated from the RTCA assays demonstrated that FA did not affect proliferation in MCF-7 cells
treated with DXR and CPT; however, FA reduced the efficacy of MMS treatment. RTCA data also
confirmed that DXR and CPT exert their cytotoxic effects in a time-dependent manner and that
CPT induced a significantly greater decrease in MCF-7 cell proliferation compared with DXR.
The MTT assay failed to detect a reduction in cell proliferation in cells treated with MMS. We
quantified the mRNA expression levels of genes associated with cellular stress response, cell cycle
and apoptosis pathways using RT-qPCR. The addition of FA to DXR or CPT promoted a similar
shift in the gene expression profile of MCF-7 cells compared with cells treated with DXR or CPT
without FA; however, this shift did not alter the bioactivity of these drugs. Rather, it indicated that
these drugs promoted cell death by alternative mechanisms. In contrast, the addition of FA to
MMS reduced the efficacy of the drug without changing the gene expression profile. None of the
genes encoding folate receptors that were analyzed were differentially expressed in cells treated withlo´gicas,
57-970,
ulfonate
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in MCF-7 cells by mRNA endpoints. Saudior without FA. In conclusion, supplementation with 450 lM FA was not cytotoxic to MCF-7 cells.
However, the addition of FA to anti-cancer drugs must be performed cautiously as the properties of
FA might lead to a reduction in drug efficacy.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Folate (folic acid) is one of the key components of one-carbon
metabolism. It plays an important role as a source of fuel to
drive the cellular functions required for growth, proliferation,
and survival, such as DNA replication and cell division. Folate
is also critical to the synthesis, repair and methylation of
DNA. The disruption of these activities can promote DNA
instability, which potentially increases the risk of carcinogenic
processes and promotes the genetic diversity underlying the
development of other hallmarks of cancer (Kim, 1999;
Negrini et al., 2010; Duthie, 2011; Hanahan and Weinberg,
2011; Crider et al., 2012; Gonen and Assaraf, 2012).
Despite these observations, the results of systematic reviews
and meta-analyses evaluating the precise role of folate defi-
ciency or supplementation in cancer development and progres-
sion and the potential role of folate in cancer prevention
remain controversial. There has been a debate as to whether
the use of folates is beneficial in primary cancer prevention,
and there are speculations that folate exerts potentially harm-
ful effects in the early stages of cancer. There is a fine balance
between preventing and promoting carcinogenesis in different
contexts depending on folate levels. For example, there are
potential tissue- and cell-specific differences in the effects of
folic acid on cellular functions (Ulrich and Potter, 2007;
Maruti et al., 2009; Wien et al., 2012; Vollset et al., 2013).
Epidemiologic studies suggest that there is an inverse corre-
lation between the risk of developing breast cancer and folate
levels. Reviews of many published case-control studies investi-
gating the potential association between dietary folate intake
and breast cancer risk have strengthened the validity of these
findings. Alternatively, the increased risk may be attributable
to a combination of chance, measurement error or other con-
founding factors. The reviews have reported both a direct and
inverse relationship that was not statistically significant,
became non-significant after adjustment, or could not be dis-
tinguished from other risk factors (Kim, 2006; Lewis et al.,
2006; Vollset et al., 2013).
It has been known for decades that the covalent attachment
of folic acid to macromolecules generates a conjugate that can
be internalized by folate receptor-bearing cells by a mechanism
similar to that employed by free folic acid. This knowledge has
been exploited for therapeutic drug delivery purposes. In addi-
tion to several other interesting features, the observation that
the folate receptor is a highly selective tumor marker overex-
pressed on the cell surface of various tumor types suggests that
folic acid might be part of a promising treatment approach for
targeted personalized cancer therapy (Leamon and Reddy,
2004; Lu and Low, 2012; Assaraf et al., 2014).
As there is no consensus on the role of folate in cancer cells
and considering that folate is used in some targeted
approaches to treating cancer, information regarding the inter-
action of folate and anti-cancer therapies is imperative to. et al., Eﬀects of folic acid on the antipr
Journal of Biological Sciences (2016), hensure the safe and proper use of this approach. Many ques-
tions regarding the effect of folate in cancer remain unan-
swered. Does folate have a protective action against cell
damage or does it further promote it? If folate has a protective
or synergistic effect, can it interfere with chemotherapy effi-
cacy? To address these issues, our study aimed to evaluate
the effects of folic acid when used in combination with the
chemotherapeutic agents doxorubicin, camptothecin and
methyl methanesulfonate in a human breast cancer cell line
(MCF-7). We investigated the potential mechanisms by which
folate interacts with these drugs with respect to cytotoxicity,
cell proliferation and gene expression.2. Materials and methods
2.1. Chemicals
Folic acid (FA) was purchased from Acros Organics
(96–100%; CAS n 66-27-3) and used at a final concentration
of 450 lM. This concentration represents a high dose of folic
acid and corresponds to a dose 50-fold greater than the folic
acid concentration in the culture medium.
To evaluate the effects of FA, the cells were treated with
doxorubicin (DXR) (CAS n23214-92-8, Adriblastina, Phar-
macia, Milan, Italy), camptothecin (CPT) (CAS n7689-03-4)
and methyl methanesulfonate; (MMS) (CAS n66-27-3) at
final concentrations of 2 lM, 3 lM and 450 lM, respectively.
These concentrations were based on previous tests performed
in our laboratory.
2.2. Cell line and culture conditions
MCF-7 cells were acquired from the Rio de Janeiro Cell Bank
and cultured in 25 cm2 bottles containing 10 mL of Dulbecco´s
Modified Eagle´s medium (DMEM – Gibco, Life Technolo-
gies, Grand Island, NY), supplemented with 10% fetal bovine
serum (FBS – Gibco) and maintained in an atmosphere of
5% CO2 at 37 C.
2.3. Cytotoxicity analysis – MTT assay
The MTT assay was performed as previously described
(Mosmann, 1983) with some modifications. The cell number
was determined using the Countess Automated Cell Counter
(Life Technologies, Grand Island, NY) and 6  103 cells/well
in a volume of 200 lL were seeded into a 96-well plate. The
plates were maintained at 37 C in a humidified atmosphere
with 5% CO2 for stabilization. After removing the media, pos-
itive control cells were treated with each chemical (2 lMDXR,
3 lM CPT and 450 lM MMS) diluted in 200 lL of culture
medium supplemented with 10% FBS. Test cells were treated
with each chemical, as described above, in combination witholiferative eﬃciency of doxorubicin, camptothecin and methyl methanesulfonate
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and a folate control (cells treated with 450 lM of FA) were
also used. After each treatment period (24 h and 48 h), the cul-
ture medium was completely removed and 100 lL of 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (CAS
298931; Sigma Aldrich, St. Louis, MO) (MTT – 0.5 mg/mL)
was added. After 4 h, the MTT solution was removed and
the formazan crystals generated were solubilized using
100 lL of DMSO. Three independent biological replicates
were used in the 8 replicate experiments of each condition.
The absorbance of the cells was measured using a spectropho-
tometer at 570 nm. The mean absorbance of each reaction was
converted to cell viability (%) using the following equation:
(mean absorbance treatment/mean absorbance control)  100.
2.4. Real Time Cell Analysis (RTCA)
Roche’s xCELLigence RTCA SP System (Mannheim,
Germany) was used to investigate the effect of FA on MCF-
7 cell proliferation using the same experimental design as
described for the MTT assay. The assay was performed
according to the manufacturer’s protocol. Briefly, a resistance
test of the equipment specific plate (a 96-well plate containing
a gold base with microelectrodes that assess the impedance of
each well in the presence of an electric field) was performed by
adding 50 lL of DMEM supplemented with 10% FBS. After
this test, 6  103 cells/well were seeded into the wells at a final
volume of 100 lL/well. Initial attachment and growth were
continuously monitored for approximately 24 h at 37 C and
5% CO2 for stabilization. Then, each chemical agent and FA
were added to the wells (final volume of 200 lL/well) and
the effects were continuously recorded every 30 min for a per-
iod of 72 h. The plate remained in the RTCA Station for 96 h,
and cell proliferation was monitored in real time and plotted
on a graph using the RTCA software. Three biological repli-
cates were evaluated in each experiment.
Changes in electrical impedance, which occur as cells
attach or detach from the surface electrodes, were measured,
evaluated by complex mathematical algorithms and plotted
as cell index (CI) values. The impedance readings can vary
based on the quality of the cell interactions and adherence
properties between cells and the electrodes. There is a direct
correlation between the number of cells attached to the elec-
trode and the number of cells attached to the electrodes with
the CI readout on the machine (Urcan et al., 2010; Pan et al.,
2013; Moniri et al., 2015). A normalized CI (NCI) value was
calculated and used to generate baseline values. The xCELLi-
gence software permits normalization to any time point, and
results can be directly viewed in the software window. We
conducted the normalization at one time point before the
treatment.
2.5. Gene expression analysis using RT-qPCR
Eight flasks were seeded with 4  104 cells/flasks in 25 cm2
flasks at a final volume of 5 mL for 24 h to allow for cell sta-
bilization. Then, each bottle received 5 mL of the indicated
treatments: flask 1 – control (complete culture medium); flask
2–450 lM FA; flask 3–2 lM doxorubicin; flask 4–2 lM dox-
orubicin +450 lM FA; flask 5–3 lM camptothecin; flask
6–3 lM camptothecin +450 lM FA; flask 7–450 lM MMS;Please cite this article in press as: Xavier, M.A. et al., Eﬀects of folic acid on the antipr
in MCF-7 cells by mRNA endpoints. Saudi Journal of Biological Sciences (2016), hand flask 8–450 lM methyl methanesulfonate +450 lM FA.
After a 24 h incubation, the culture medium was removed
and the total RNA was extracted using TRIzol (Invitrogen
Life Technology, Grand Island, NY) and the RNeasy Mini
Kit (Qiagen, Valencia, CA–Cat. n74106) according to the
supplier’s instructions. The experiments were performed in
triplicate. The purity and concentration of the isolated RNA
were determined using a spectrophotometer, and RNA integ-
rity was evaluated using denaturing agarose gel electrophoresis
as previously described (Aranda et al., 2012).
cDNA synthesis reactions were performed in triplicate for
each sample in a T100 Thermal Cycler (BIO-RAD, Singapore)
using 500 ng of total RNA diluted in a final volume of 16 lL,
8 lL of DEPC-treated water, 4 lL of oligo dT (20 pmol/lL)
and 4 lL of dNTPs (2.5 mM). The first reaction mix was incu-
bated for 10 min at 65 C. Each reaction was subjected to ther-
mal shock in ice. Then, 4 lL of a second reaction mix was
added [1.3 lL of DEPC-treated H2O, 2 lL of 10 buffer,
0.6 lL of MgCl2 (50 mM), 0.05 lL of RNase Out (Invitrogen)
and 0.05 lL of M-MLV enzyme (Invitrogen)]. The final solu-
tion was incubated at 37 C for 50 min to allow cDNA synthe-
sis to proceed, and the enzymatic reaction was terminated at
70 C for 15 min.
The qPCR reactions were also performed in triplicate in a
CFX96TM Real-Time System (BIO-RAD, Singapore) using
5 lL of Platinum SYBR Green qPCR Supermix-UDG (Invit-
rogen), 1 lL of each oligonucleotide primer (10 pmol/lL) and
5 lL of cDNA (50 ng/lL) (1:10 dilution of input RNA). The
reaction conditions were as follows: pre-incubation at 50 C
for 2 min (UDG incubation), initial denaturation at 95 C
for 5 min; and 40 cycles of 95 C for 20 s, 60 C for 30 s and
72 C for 20 s. A melting curve analysis ranging from 55 C
to 95 C was generated at the end of the reaction, with 5 s
readings at every 0.5 C. The software CFX Manager 3.1
(BIO-RAD) was used to collect the data and the efficiency of
the reactions was calculated using LinRegPCR software
(Amsterdam, the Netherlands), as previously described
(Ruijter et al., 2009).
Predesigned KiCqStart SYBR Green primers (Sigma–
Aldrich) were used for the qPCR reactions and GAPDH was
used as the reference gene. The following target genes were
evaluated: FOLR1, SLC19A1 and SLC46A1 (encoding the
folate receptors FRa, RFC and PCFT, respectively);
GADD45A, DDIT3, BIRC5, CCNA2 and TP53 (genes associ-
ated with the DNA damage response and cell cycle regulation);
and BAK, BAX, BCL-2, BCL-XL, CASP7, CASP8 and
CASP9 (genes associated with apoptosis).
2.6. Statistical analysis
The absorbance values obtained from the MTT assay and
RTCA cell index were compared using ANOVA and Tukey’s
test (p< 0.05) using GraphPad Prism 5 software
(San Diego, CA). Statistical evaluation of reference gene and
test gene expression levels were performed using the stand-
alone software REST 2009 (Relative Expression Software
Tool, M. Pfaffl, Munich, Germany and QIAGEN, Hilden,
Germany) as previously described (Pfaffl et al., 2002) with
efficiency correction. A statistically significant difference was
defined as a 2-fold change in expression and a p-value <0.05
compared with the corresponding control.oliferative eﬃciency of doxorubicin, camptothecin and methyl methanesulfonate
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The absorbance values obtained from the MTT assay after 24
and 48 h of treatment were converted to percentages of cell
viability (Fig. 1). No significant effect on viability was
observed in cells treated with only folic acid (FA) compared
with the control cells at both time points evaluated. The viabil-
ity of MCF-7 cells after 24 h of treatment with DXR, CPT and
MMS was 67.12%, 39.31% and 38.93%, respectively. After
48 h, the viability continued to decline significantly in cells
treated with DXR (37.66%) and CPT (15.48%) but remained
unchanged in cells treated with MMS (35.80%).
At both time points analyzed, CPT induced a significantly
greater decrease in MCF-7 cell viability compared with DXR.
At 24 h, the reduction in cell viability induced by MMS treat-
ment was similar to the reduction observed with CPT, and
the reduction in cell viability induced by DXR was significantly
compared with MMS and CPT. However, the effects of MMS
in MCF-7 cells stabilized after 48 h, and the reduction in cell
viability was surpassed by CPT and was equivalent to DXR,
which continued to decrease cell viability after 24 h. DXR
and CPT, but not MMS, exerted their cytotoxic effects in a
time-dependent manner. The cytotoxic profiles of all three
drugs were unaffected by the addition of FA. The viability of
cells treated with FA in combination with DXR, CPT and
MMS was 69.46%, 44.45% and 40.17%, respectively, at 24 h,
and 37.95%, 17.67% and 33.27%, respectively, at 48 h.
To ensure that the cytotoxicity observed in the MTT assay
was associated with the reduction in the proliferation of MCF-
7 cells, promoting a cytostatic effect and/or death, we
conducted a Real Time Cell analysis (RTCA). The RTCA
monitoring of MCF-7 cells proliferation was performed for
72 h after the addition of treatment. The results are plotted
in Fig. 2. There was no significant effect on the proliferation
of cells treated with FA only compared with the control. The
RTCA data from cells treated with DXR and CPT were con-
sistent with the results of the MTT assay, which demonstrated
no significant differences in the anti-proliferative effect of
DXR, CPT and MMS when used alone or in combination with
FA. Similar to the MTT assay, the RTCA demonstrated that
DXR and CPT decrease cell viability in a time-dependentFigure 1 MCF-7 cells treated with doxorubicin (DXR), camptothecin
or without the addition of folic acid (FA) were evaluated using the M
Letters represent statistically significant differences between treatment
between the 24 h and 48 h treatments.
Please cite this article in press as: Xavier, M.A. et al., Eﬀects of folic acid on the antipr
in MCF-7 cells by mRNA endpoints. Saudi Journal of Biological Sciences (2016), hmanner and that CPT induces a significantly greater decrease
in MCF-7 cell proliferation compared with DXR. The cellular
index (CI) of cells treated with CPT obtained at 24 h (0.0782)
was approximately 50% of the CI value obtained for cells trea-
ted with DXR (0.1573).
The RTCA data revealed that CPT and DXR exhibited sim-
ilar proliferation profiles in the first 10 h following treatment.
After 10 h, CPT induced a greater CI reduction compared with
DXR. After 15 h of treatment, we detected a 2:1 ratio between
the CI of DXR- and CPT-treated cells. This correlation was
observed at all other points analyzed until the curves began
to decline, demonstrating the significantly faster action of
CPT compared with DXR inMCF-7 cells. TheMTT assay can-
not provide this type of information. The RTCA also revealed
that both drugs killed nearly the entire cell population after
approximately 24 h of treatment. In contrast, the MTT assay
indicated a continuous reduction in cell viability until 48 h.
Additionally, in contrast to the MTT assay outcomes,
RTCA data revealed that MMS treatment did not provide a
greater reduction in MCF-7 cell viability compared with
DXR after 24 h. The differences between the effects of the
drugs were more evident at 48 h. The MTT assay revealed that
cell viability was similar in cells treated with DXR and MMS.
However, the RTCA data revealed that cell viability was sig-
nificantly lower in cells treated with DXR compared with
CPT at 48 h. In fact, at both the 24 and 48 h time points, cell
viability was significantly lower in cells treated with DXR and
CPT compared with MMS. The proliferation curves associated
with DXR and CPT exhibited a steeper decline compared with
MMS, which exhibited a partial reduction followed by a recov-
ery of proliferation.
In contrast to DXR and CPT, the anti-proliferative effect
of MMS was influenced by FA. FA significantly diminished
the anti-proliferative effect of MMS as early as 10 h after treat-
ment. At this time point, the CI values of the control, MMS
and MMS+ FA groups were 1.5415, 1.0370 and 1.1158,
respectively. The reduction in MMS activity induced by FA
significantly increased over the incubation time. After 24 h,
the CI values of the control, MMS and MMS+ FA groups
were 2.7632, 0.6489 and 0.8202, respectively.
In addition, proliferation significantly recovered after
approximately 30 h in MCF-7 cells treated with MMS and(CPT) or methyl methanesulfonate (MMS) for 24 h and 48 h with
TT assay. The values in the column represent the mean ± S.D.
s (24 or 48 h). (*) represents the statistically significant difference
oliferative eﬃciency of doxorubicin, camptothecin and methyl methanesulfonate
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Figure 2 Real Time Cell Analysis (RTCA) of MCF-7 cells treated with (a) doxorubicin (DXR), (b) camptothecin (CPT) or (c) methyl
methanesulfonate (MMS) with or without the addition of folic acid (FA). Cells were analyzed 72 h after the addition of treatment.
Effects of folic acid on the antiproliferative efficiency 5MMS+ FA, and the significant difference in the viability of
these 2 groups was maintained. At 48 h, the CI values of
MMS- and MMS+ FA-treated cells were 1.6320 and
2.3180, respectively. As was previously observed, the MTT
assay did not detect the restoration of MCF-7 cell growth at
48 h or the significant difference in the viability of MMS-
and MMS+ FA-treated cells. At 72 h, RTCA revealed that
the CI values of the control, MMS and MMS+ FA groups
changed to 3.4196, 2.4951 and 3.1767, respectively. In sum-
mary, both proliferation curves (MMS and MMS+ FA) are
significantly different from the control, and the addition of
FA significantly impaired the efficacy of MMS treatment.
The MTT assay was unable to detect these differences.
Gene expression data were analyzed using REST 2009, and
the results are plotted in Fig. 3. The reference gene GAPDH
was validated and proved that there is no statistically signifi-
cant difference between the analyzed conditions by the same
software. The expression ratio is the median value obtained
from all the experiments performed in each condition. We ana-
lyzed the gene expression levels of the folate receptors FOLR1,
SLC19A1 and SLC46A1 in response to DXR, CPT and MMS
treatments with or without FA. No significant differences in
gene expression were observed between the 2 conditions (data
not shown).
We analyzed a set of genes involved in stress signaling, cell
cycle and apoptosis pathways (GADD45A, DDIT3, BIRC5,
CCNA2, TP53, BAX, BAK, BCL-XL, BCL-2, CASP7, CASP8
and CASP9). None of the genes evaluated were differentially
expressed in cells treated with FA only compared with the con-
trol, demonstrating that folate treatment alone does not alter
the normal expression levels of these genes in MCF-7 cellsPlease cite this article in press as: Xavier, M.A. et al., Eﬀects of folic acid on the antipr
in MCF-7 cells by mRNA endpoints. Saudi Journal of Biological Sciences (2016), hunder the conditions evaluated in this study. Both DXR and
CPT significantly reduced the expression of all the target genes
evaluated. There was a decline in the expression of BAK and
CASP7 in viable cells treated with DXR; however, the reduc-
tion was not significantly compared with the control.
The addition of FA to DXR and CPT significantly altered
gene expression profiles. In cells treated with DXR or CCPT in
combination with FA, the gene expression levels of GADD45A
and DDIT3 increased compared with the control, and the
expression levels of BAX, BAK, BCL-XL, BCL-2, CASP7,
CASP8 and CASP9 were restored to normal levels (equivalent
to the control). However, as demonstrated by the MTT assay
and RTCA, the shift in the gene expression profiles did not
influence the cytotoxic effects of DXR and CPT.
In summary, the addition of FA to DXR and CPT treat-
ments significantly increased the expression of genes whose
expression levels decreased in cells treated with DXR or CPT
only (in the absence of FA), with the exception of TP53,
BIRC5 and CCNA2, which were expressed at similar levels
in the presence or absence of FA. These results demonstrate
that DXR and CPT induce similar changes in gene expression
profiles generated when administered without FA and induce a
similar response to the addition of FA in MCF-7 cells.
In contrast to DXR and CPT, the addition of FA to MMS
did not induce significant changes in gene expression. DXR
and CPT significantly increased the expression of GADD45A
and DDIT3 and decreased the expression of TP53, BIRC5
and CCNA2. We observed a trend in which pro-apoptotic
genes (BAX and BAK) were up-regulated and anti-apoptotic
genes (BCL-XL and BCL-2) were down-regulated in cells trea-
ted with MMS with or without the addition of FA.oliferative eﬃciency of doxorubicin, camptothecin and methyl methanesulfonate
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Figure 3 Relative gene expression levels in MCF-7 cells treated for 24 h with doxorubicin (DXR), camptothecin (CPT) or methyl
methanesulfonate (MMS) with or without folic acid (FA) were evaluated using RT-qPCR. (*) represents a statistically significant
difference between the treatments with and without FA compared with the control.
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In recent years, the free radical scavenging properties and
antioxidant activity of folic acid have been demonstrated
(Joshi et al., 2001; Gliszczynska-Swigło, 2007; Sarna et al.,
2012). As the addition of FA was the only difference between
the conditions evaluated in this study, we postulate that the
antioxidant effects of FA modulate gene expression in MCF-
7 cells treated with DXR and CPT.
Several studies have scrutinized the sensitivity and accuracy
of cytotoxicity end-point assays. These studies compared the
strengths and weaknesses of the most commonly used assays,
especially the MTT assay (Sieuwerts et al., 1995; Lobner,
2000; Putnam et al., 2002; Weyermanna et al., 2005; Fotakis
and Timbrell, 2006; Scherlie, 2011). They emphasize the rele-
vance of using the appropriate assay to avoid overestimating
or underestimating the toxicity of a substance and to reduce
the risk of false-positive or false-negative results. These studies
also indicate that more than one assay should be used to eval-
uate cytotoxicity in vitro. It is not possible to rely solely on the
results of 1 method. The results of different assays can widely
vary as the methods are based on different mechanisms. ThePlease cite this article in press as: Xavier, M.A. et al., Eﬀects of folic acid on the antipr
in MCF-7 cells by mRNA endpoints. Saudi Journal of Biological Sciences (2016), hresults can also vary as a result of the particular mechanism
of action of the substance analyzed or other technical factors.
In addition, to increase the reliability of the results, incuba-
tions with various concentrations of a substance at many time
points and microscopic analysis of cell cultures before and
after performing an assay are recommended.
FA does not affect the cytotoxicity and anti-proliferative
effects promoted by DRX and CPT in MCF-7 cells; however,
FA reduces the efficacy of MMS. Accordingly, the failure of
the MTT assay to detect the actual influence of folic acid on
MMS activity in our study is not surprising. Other studies have
also described discrepancies between metabolic-based MTT
and impedance-based viability assays. These reports suggest
that data generated using RTCA reflects cellular viability more
accurately and is not influenced by metabolic status, indicating
that it is a more sensitive and suitable method for evaluating
antineoplastic agents (Gumulec et al., 2014a,b). Therefore,
the results observed in our study confirmed the advantages
of RTCA that have been previously described. In addition,
our findings indicate that RTCA overcomes the limitations
associated with the MTT assay and can more accurately assess
the effects of FA, such as the reduction in efficacy of MMS inoliferative eﬃciency of doxorubicin, camptothecin and methyl methanesulfonate
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tics. In summary, the RTCA system has proven to be a more
reliable and informative technique to evaluate cytotoxicity
in vitro and demonstrates that FA does not affect the cytotox-
icity and antiproliferative effect of DRX and CPT, but it does
reduce the efficacy of MMS in MCF-7 cells.
Our results also suggest that folic acid supplementation to
the chemotherapeutics evaluated in this study does not influ-
ence the expression of genes encoding folate receptors. The
expression levels of the folate receptors FOLR1, SLC19A1
and SLC46A1 were not significantly different in cells treated
with DXR, CPT and MMS compared with cells treated with
DXR, CPT and MMS in combination with FA.
DXR and CPT have similar (but not equal) mechanisms of
action that promote similar cellular responses (Li et al., 2006;
Thorn et al., 2011; Tacar et al., 2013; Dezhenkova et al., 2014).
DXR binds to multiple DNA-associated enzymes, including
topoisomerases I and II, to induce a range of cytotoxic effects.
The generation of free radicals and the damaging effects of free
radicals on cellular membranes, DNA and proteins are addi-
tional cytotoxic mechanisms employed by DXR and CPT.
Both drugs can induce antiproliferative effects and DNA dam-
age, thereby triggering apoptotic cell death pathways when
attempts to repair DNA breaks fail and cell cycle progression
arrests at the G1 and G2 phases (Thorn et al., 2011; Tacar
et al., 2013; Dezhenkova et al., 2014). CPT binds to the topoi-
somerase I-DNA complex, which results in the accumulation
of DNA double stranded breaks during replication. CTP also
exerts a range of cytotoxic effects that ultimately cause cell
death. CTP-induced cytotoxicity is especially pronounced dur-
ing the S-phase of the cell cycle as it is more toxic to cells
undergoing DNA synthesis. ROS production is also involved
in CPT-induced apoptosis (Li et al., 2006; Dezhenkova et al.,
2014). Our results confirm that CPT and DXR exert similar
cytotoxic effects in MCF-7 cells as the cytotoxic profile and
the proliferation curves, obtained by MTT and RTCA assays,
respectively, were similar for the 2 drugs. The primary differ-
ence between DXR and CPT was the intensity of their effects.
Our results showed that, despite the FA-induced changes in
gene expression, the capacity of DXR and CPT to promote cell
death was unaffected by FA. Therefore, the antioxidant prop-
erties of FA might protect MCF-7 cells from damage induced
by ROS formation when administered in combination with
DXR and CPT. We hypothesize that the similar changes in
gene expression induced by DXR and CPT result from the
ROS formation associated with the mechanism of cell death
exhibited by these drugs. When DXR and CPT are adminis-
tered in combination with FA, FA’s free radical scavenging
and antioxidant properties might neutralize the effects of
ROS and trigger a shift in gene expression consistent with a
response to a mechanism of cell death independent of ROS.
There are two partially interconnected apoptotic mecha-
nisms, caspase-dependent classical apoptosis and caspase-
independent programed cell death. The two forms of cell death
might be interconnected and potentially lead to the activation
of non-caspase proteases (Ola et al., 2011; Chaabane et al.,
2013). As reviewed by Sinha et al. (2013), an alternative path-
way modulated by oxidative stress can also promote apoptosis
independent of CASP7, CASP8 and CASP9 by activating
TNFa. In this alternative pathway, the receptor-interacting
protein (RIP) binds to TNFR1-associated death domain
(TRADD) and ultimately activates caspase-2. This activationPlease cite this article in press as: Xavier, M.A. et al., Eﬀects of folic acid on the antipr
in MCF-7 cells by mRNA endpoints. Saudi Journal of Biological Sciences (2016), hwas reported to potentially be a response to severe stress and
to promote rapid cell death.
In our study, DXR and CPT treatment of MCF-7 cells
resulted in the down-regulation of the CASP7, CASP8 and
CASP9 genes. Moreover, the release of AIF from the mito-
chondria can be prevented by the overexpression of Bcl-2
(Yu et al., 2003; Ola et al., 2011); however, our data revealed
that the BCL-2 gene was down-regulated in response to
DXR and CPT treatments.
Our results also demonstrated that the TP53 gene is down-
regulated in MCF-7 cells treated with DXR and CPT. How-
ever, TP53 overexpression is normally observed in the classical
apoptotic pathways. In fact, all classical pro-apoptotic (BAX
and BAK) and anti-apoptotic (BCL-2 and BCL-XL) genes
are down-regulated by both treatments, as previously
described.
GADD45A and DDIT3 play significant roles in the response
to cellular genotoxic and non-genotoxic stress, whereby they
function as stress sensors and tumor suppressors. The expres-
sion of GADD45A and DDIT3 are rapidly induced by DNA
damage and they promote cell cycle arrest and/or apoptosis
or actively participate in DNA repair mechanisms
(Liebermann and Hoffman, 2008; Tamura et al., 2012). Our
RT-qPCR results demonstrated that the GADD45A and
DDIT3 genes were down-regulated in MCF-7 cells treated with
DXR and CPT, indicating that the induction of these genes
was not a result of DNA damage. These results suggest that
these agents primarily promote cell death by an alternative
mechanism. Some authors corroborated that apoptosis may
be attributable to off-target effects independent of DNA dam-
age (Havelka et al., 2007).
Methyl methanesulfonate (MMS) is an alkylating agent
capable of randomly inducing DNA lesions that lead to single
and double strand breaks in genomic DNA. In response to this
damage, the cell cycle arrests and repair pathways are acti-
vated. Once the DNA repair process is complete, cell cycle pro-
gression can resume. Alternatively, if the damage cannot be
repaired, cell death mechanisms are initiated (Schwartz and
Kmiec, 2005; Kondo et al., 2010).
Our RTCA results demonstrated that proliferation was
restored in MCF-7 cells after 30 h of treatment with either
MMS+ FA or MMS. Therefore, it is possible that the cyto-
toxicity observed in the MTT assay reflects a decrease in
metabolically active cells due to cell cycle arrest rather than
a decrease in cellular viability due to cell death. This type of
effect has been previously reported by other groups
(Schwartz and Kmiec, 2005).
Our gene expression results also support this hypothesis.
We showed that MMS and MMS+ FA treatments increased
the expression of GADD45A and DDIT3, genes activated by
DNA damage and significantly reduced the expression of the
TP53, BIRC5 and CCNA2 genes, indicating that cell cycle
arrest had occurred. However, the expression levels of pro-
apoptotic and anti-apoptotic genes did not change. These find-
ings, coupled with the observation that proliferation recovers
in cells treated with MMS or MMS+ FA indicate that most
MCF-7 cells did not undergo cell death but underwent DNA
damage repair in response to the cytotoxic effects of MMS
with or without FA. Together, our results demonstrate that
folic acid promoted a similar shift in the gene expression pro-
files of MCF-7 cells treated with DXR and CPT but did not
alter the expression profile of MCF-7 cells treated with MMS.oliferative eﬃciency of doxorubicin, camptothecin and methyl methanesulfonate
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Our study emphasizes the need for increased awareness about
the choice of tests for analyzing cell viability in vitro. Our study
revealed that the RTCA system is more accurate, sensitive and
reliable compared with the MTT assay. We demonstrated that
450 lM of FA supplementation is not cytotoxic to MCF-7
cells and does not alter the expression of folate receptor genes
even in combination with the chemotherapeutic drugs evalu-
ated in this study. However, the addition of FA to chemother-
apy drugs must be performed cautiously, as the antioxidant
properties of FA might not always be beneficial and might
interfere with the mechanisms underlying drug efficacy.
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